CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性 B 细胞血液系统恶性肿瘤中 CD19 靶向 CAR-T 细胞治疗的细胞因子释放综合征及相关因素
英文原题：Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies.
查看英文原题
Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
作为 CAR-T 治疗的常见不良反应，CRS 的严重程度可通过剂量递增输注减轻，移植史与较轻的 CRS 相关。
中文摘要
结果
完全缓解（CR）率为 74.0%（57/77）。77 个疗程中有 68 个（88.3%）发生任何级别 CRS，1、2、3、4 和 5 级分别占 32.5%、24.7%、22.1%、6.5% 和 2.6%。有移植史的患者 CRS 较轻；基于剂量递增的输注可降低 CRS 严重程度。重度 CRS 与较高 CR 率相关，但对无事件生存期（EFS）、无复发生存期（RFS）或总生存期（OS）无显著影响。
结论
CRS 是 CAR-T 治疗的常见不良反应，可通过剂量递增输注减轻其严重程度；移植史与较轻 CRS 相关。重度 CRS 与较好应答相关，但与长期生存无关。
展开英文摘要原文
RESULTS
The rate of complete remission (CR) was 74.0% (57/77). CRS of any grade occurred in 68 of 77 episodes (grade 1: 32.5%, grade 2: 24.7%, grade 3: 22.1%, grade 4: 6.5%, grade 5: 2.6%). Patients with a history of transplantation had less severe CRS, and dose escalation-based infusion reduced the severity of CRS. Severe CRS was related to a higher CR rate but had no significant impact on event-free survival (EFS), relapse-free survival (RFS), or overall survival (OS).
CONCLUSION
As a common adverse reaction of CAR-T therapy, the severity of CRS can be alleviated by dose escalation infusion, a history of transplantation was correlated with less severe CRS. Severe CRS was related to better response but was unrelated to long-term survival.
论文信息
- 作者
- Xu QW、Xu H、Xue L、Wang L、Zhang XH、Song KD、Yao W、Wan X
- 第一作者单位
- Department of Hematology, The First Affiliated Hospital of USCT (Anhui Provincial Hospital), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.China
- 通讯作者单位
- Department of Hematology, The First Affiliated Hospital of USCT (Anhui Provincial Hospital), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China. Electronic address: wangxingbing@ustc.edu.cn.China
- 期刊
- Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2022 Dec
- 原文标识
- PubMed 35672235 · DOI 10.1016/j.transci.2022.103473